19 May 2013
Keywords: gsk, licenses, galapagos, anti-infectives, uk, drug, major
Article | 17 December 2007
UK drug major GlaxoSmithKline has licensed product candidates from Galapagos NV directed against up to six anti-infective targets. As part
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 December 2007
17 May 2013
© 2013 thepharmaletter.com